Bioinspired nanovectors for CRISPR/Cas9-mediated CAR T cell manufacturing - Project Summary
Adoptive cell therapy using patient-specific T cells engineered with chimeric antigen receptors (CARs) presents
a promising treatment modality for cancer patients. However, FDA-approved CAR T cells are genetically
engineered by viral transduction, a process that poses limitations for manufacturing and in vivo translation. Viral
production is prohibitively expensive and is a main driver of the high price of CAR T cell therapy ($350–450K per
treatment). Additionally, batch production of viral vectors requires a minimum 4+ week lead time. This long
duration in therapeutic cell manufacturing can delay treatments for patients with progressive diseases. Moreover,
due to safety concerns associated with viral transduction (e.g., insertional mutagenesis), the FDA regulates the
number of integrated viral vectors per T cell to 5 copies, which limits the number of viral particles used for
transduction and results in low transduction efficiencies. These issues are a barrier to optimization of CAR
design, expanding clinical applications, and broad patient access to CAR T cell therapies. Therefore, the overall
goal of this proposal is to develop a new non-viral transfection system to achieve rapid and cost-efficient CAR T
cell manufacturing. This system consists of bioinspired nanovectors that mimics the biological activity of
endogenous serum proteins to enhance CAR transgene delivery to primary T cells. Preliminary data supporting
this proposal demonstrates that the bioinspired nanovectors were internalized by activated T cells more
efficiently than conventional nanoparticle formulations, such as liposomes. The bioinspired nanocarriers
therefore overcome the low endocytic capability of primary T cells, a delivery barrier faced by other nanoparticle-
based transfection reagents. To achieve persistent CAR expression, this system will use CRISPR/Cas 9 for site-
specific CAR insertion into the T cell genome, which mitigates safety concerns resulting from virus-induced
random insertions. This proposal will also leverage high-throughput, scalable microfluidic reactors to accelerate
the nanocarrier optimization at the exploratory phase and allow future clinical translation of the proposed non-
viral transfection system for CAR T cell manufacturing. The specific aims of this proposal are to (1) optimize
bioinspired nanovectors for non-viral CAR T cell manufacturing, and to (2) benchmark anticancer efficacy of the
non-virally transfected CAR T cells against virally transduced counterparts. Successful completion of this project
will lead to a new CAR T cell manufacturing process that accelerates CAR T cell development for clinical
translation, facilitates compliance with regulations, and reduces the manufacturing costs and lead times to
democratize CAR T cell therapy.